论文部分内容阅读
目的了解重症社区获得性肺炎(Serious community acquired pneumonia,SCAP)患儿分离的肺炎链球菌药敏情况,为救治过程合理使用抗菌药物、有效控制感染提供参考依据。方法回顾性分析2010年1月至2012年6月在我院救治的131例SCAP患儿吸痰分离的肺炎链球菌药敏情况。结果分离出肺炎链球菌74株,四环素、红霉素耐药率>91%,不含抑酶类β-内酰胺抗菌药物的耐药率为37%～46%,喹诺酮类及氯霉素耐药率<10%,利奈唑胺、泰利霉素耐药率也较低,碳青霉烯类表现出中介甚至耐药,未发现万古霉素耐药菌株。结论 SCAP患儿分离的肺炎链球菌以多重耐药菌株为主,经验用药面临挑战,病原菌培养药敏试验对于制定更好治疗方案具有重要意义。
Objective To understand the susceptibility of Streptococcus pneumoniae isolated from children with Serious community acquired pneumonia (SCAP) and to provide a reference for rational use of antimicrobial agents in the treatment process and effective control of infection. Methods The susceptibility of S. pneumoniae isolated from sputum of 131 children with SCAP who were treated in our hospital from January 2010 to June 2012 was retrospectively analyzed. Results 74 strains of Streptococcus pneumoniae were isolated. The rates of resistance to tetracycline and erythromycin were 91%, 37% to 46% respectively. The resistance rates of quinolones and chloramphenicol The drug resistance rate was lower than 10%. The linezolid and telithromycin rates were also lower. The carbapenems showed intermediate or even drug resistance. No vancomycin resistant strains were found. Conclusions Streptococcus pneumoniae isolated from children with SCAP are mainly multi-drug resistant strains, and experience medication is challenged. The susceptibility testing of pathogen culture is of great significance for the development of a better treatment plan.